Amikacin Inj

Compare Amikacin Inj  to:
Compare
Compare

Generic Name for Amikacin Inj

Amikacin sulfate 100mg/2mL, 500mg/2mL, 1g/4mL; soln for IM inj or IV infusion after dilution; contains sulfites.

Legal Classification:

Rx

Pharmacological Class for Amikacin Inj

Aminoglycoside.

Manufacturer of Amikacin Inj

Various generic manufacturers

Indications for Amikacin Inj

Short-term treatment of serious susceptible infections, including septicemia, respiratory tract, bones and joints, CNS (eg, meningitis), skin and skin structure, intra-abdominal (eg, peritonitis), burns and postoperative infections, complicated and recurrent UTIs or uncomplicated UTIs not susceptible to other antibiotics.

Adult dose for Amikacin Inj

Give by IM inj; or IV infusion over 30–60 mins. 15mg/kg per day in 2–3 divided doses (7.5mg/kg every 12 hours or 5mg/kg every 8 hours); max 15mg/kg/day. Heavier wt. patients: max 1.5g/day. Usual duration: 7–10 days. Uncomplicated UTIs: 250mg twice daily. Renal impairment: adjust dose based on serum levels or reduce frequency; see literature.

Children's dosing for Amikacin Inj

Infants: give by IM inj; or IV infusion over 1–2 hours. Newborns: loading dose: 10mg/kg; then follow with 7.5mg/kg every 12 hours. All other children and older infants: give by IM inj; or IV infusion over 30–60 mins. 15mg/kg per day in 2–3 divided doses (7.5mg/kg every 12 hours or 5mg/kg every 8 hours); max 15mg/kg/day. Usual duration: 7–10 days. Renal impairment: adjust dose based on serum levels or reduce frequency; see literature.

Precautions for Amikacin Inj

Monitor for nephro- and neurotoxicity; avoid peak serum levels >35micrograms/mL and trough levels >10micrograms/mL. Discontinue or adjust dose if auditory, vestibular, or renal dysfunction develops; monitor serum levels periodically. Monitor BUN, CrCl, serum creatinine levels before, frequently during, and after therapy. Perform audiogram in high-risk patients. Maintain adequate hydration. Prolonged use or excessive doses. Asthma. Muscular disorders (eg, myasthenia gravis, parkinsonism, or infant botulism). Elderly. Premature or neonatal infants. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.

Interactions for Amikacin Inj

Avoid concomitant furosemide, ethacrynic acid. Diuretics may increase toxicity. Increased risk of neurotoxicity and/or nephrotoxicity with concurrent or sequential polymyxin B, colistin, amphotericin B, other nephrotoxic or neurotoxic drugs; avoid. May potentiate neuromuscular blockade, respiratory paralysis with anesthetics, neuromuscular blockers. May be antagonized by concomitant penicillins, cephalosporins.

Adverse Reactions for Amikacin Inj

Nephrotoxicity (eg, azotemia, oliguria), ototoxicity, neurotoxicity, neuromuscular blockade (eg, muscular paralysis, apnea); rare: rash, drug fever, headache, tremor, GI upset, paresthesia, eosinophilia, arthralgia, anemia, hypotension, hypomagnesium.

How is Amikacin Inj supplied?

Contact supplier.

Related Disease:

Infections, bacterial~systemic antiinfectives

Related Resources

Cayston inhaled antibiotic approved for cystic fibrosis

February 23, 2010

The FDA has approved Cayston (aztreonam for inhalation solution, from Gilead Sciences) as a treatment to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa.

Phase 3 study of fidaxomicin for clostridium difficile infection (CDI)

February 05, 2010

Optimer Pharmaceuticals announced positive top-line results from the second of two Phase 3 trials evaluating the safety and efficacy of fidaxomicin (OPT-80) in patients with Clostridium difficile Infection (CDI).

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Phase 2 study of Arikace for treatment of pseudomonas lung infections

October 19, 2009

Transave reported additional positive clinical trial results on its lead investigational drug, Arikace (liposomal amikacin for inhalation), an antibiotic to treat chronic lung infections.

Vibativ approved for complicated skin and skin structure infections

September 18, 2009

The FDA has approved Vibativ (telavancin, from Theravance and Astellas), a bactericidal, once-daily injectable lipoglycopeptide antibiotic.